Typically, chronic red blood cell transfusion therapy is utilized in SCA for stroke prevention with a primary goal of maintaining Hb S <30%, which may result in a nadir Hb pre-transfusion of <8 g/dl (33). This evidence concerns the gene GSTM1 and autosomal dominant cerebellar ataxia.